WEGOVY FLEXTOUCH Drug Patent Profile
✉ Email this page to a colleague
When do Wegovy Flextouch patents expire, and when can generic versions of Wegovy Flextouch launch?
Wegovy Flextouch is a drug marketed by Novo and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in WEGOVY FLEXTOUCH is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.
DrugPatentWatch® Generic Entry Outlook for Wegovy Flextouch
Wegovy Flextouch was eligible for patent challenges on December 5, 2021.
There is one tentative approval for the generic drug (semaglutide), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
US Patents and Regulatory Information for WEGOVY FLEXTOUCH
WEGOVY FLEXTOUCH is protected by five US patents and two FDA Regulatory Exclusivities.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | WEGOVY FLEXTOUCH | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-012 | Jun 18, 2026 | RX | Yes | Yes | 12,551,536 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | WEGOVY FLEXTOUCH | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-012 | Jun 18, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | WEGOVY FLEXTOUCH | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-012 | Jun 18, 2026 | RX | Yes | Yes | 9,764,003 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | WEGOVY FLEXTOUCH | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-012 | Jun 18, 2026 | RX | Yes | Yes | 12,029,779 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | WEGOVY FLEXTOUCH | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-012 | Jun 18, 2026 | RX | Yes | Yes | 11,478,533 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for WEGOVY FLEXTOUCH
See the table below for patents covering WEGOVY FLEXTOUCH around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 112480 | ⤷ Start Trial | |
| Australia | 2018321157 | ⤷ Start Trial | |
| Australia | 2024204151 | ⤷ Start Trial | |
| Brazil | 112020002804 | ⤷ Start Trial | |
| Canada | 3082033 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for WEGOVY FLEXTOUCH
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1863839 | SPC/GB18/023 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208 |
| 1863839 | 1890018-3 | Sweden | ⤷ Start Trial | PRODUCT NAME: SEMAGLUTIDE; REG. NO/DATE: EU/1/17/1251 20180212 |
| 1863839 | 132018000000262 | Italy | ⤷ Start Trial | PRODUCT NAME: SEMAGLUTIDE(OZEMPIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1251, 20180212 |
| 1863839 | 2018C/016 | Belgium | ⤷ Start Trial | PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212 |
| 1863839 | 122018000075 | Germany | ⤷ Start Trial | PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch